An extraction-free, lyophilized one-pot RAA-CRISPR assay for point-of-care testing of <i>Haemophilus influenzae</i>
Timely and accurate diagnosis is essential for the effective treatment of <i>Haemophilus influenzae</i> (HI) infection. Notably, a rapid point-of-care testing (POCT) method for the diagnosis of HI DNA is still lacking. The aim of this study was to establish a one-pot detection device for HI DNA detection using CRISPR/Cas13a that would be applicable for POCT. We established a two-step polymerase chain reaction (PCR)-CRISPR assay, a two-step recombinase-aided amplification (RAA)-CRISPR assay, and a one-pot RAA-CRISPR assay. Additionally, reagent lyophilization, rapid lysis technology, and a one-pot detection device were integrated to construct an extraction-free one-pot detection device, named EFORCA (extraction-free one-pot RAA-CRISPR/Cas13a assay). Validation was performed on 90 simulated samples and 77 clinical samples. The two-step PCR/RAA-CRISPR assay for HI DNA detection was established and optimized, with a detection limit of 1 copy/μL and 100% specificity. The sensitivity and specificity of the two-step PCR-CRISPR assay for the 90 simulated clinical samples were 96.7% and 95%, respectively, and for the 77 clinical samples, 97.5% and 100%, respectively. The one-pot RAA-CRISPR assay and the EFORCA detected 50 and 25 CFU/mL HI in bacterial suspensions within 30 min, respectively. The valuation results for 77 clinical samples demonstrated that the sensitivity of both methods was 95%, which was greater than the sensitivity of quantitative real-time PCR (qPCR) (92.5%) with the same specificity of 100%. We developed an extraction-free one-pot RAA-CRISPR/Cas13a assay for HI detection, which effectively performs a POCT test and is a valuable tool for the early detection and monitoring of HI infection.IMPORTANCETimely and accurate diagnosis is essential for the effective treatment of <i>Haemophilus influenzae</i> (HI) infection. Notably, a rapid point-of-care testing (POCT) method for the diagnosis of HI DNA is still lacking. In this study, sensitive two-step polymerase chain reaction (PCR)-CRISPR and recombinase-aided amplification (RAA)-CRISPR assays were developed, followed by the establishment of the one-pot RAA-CRISPR assay through integration of RAA, CRISPR, and rapid lysis for HI detection. Additionally, reagent lyophilization, rapid lysis technology, and a one-pot detection device were integrated to construct the extraction-free one-pot RAA-CRISPR/Cas13a assay (EFORCA). With its high sensitivity, specificity, rapid turnaround time, and operational simplicity, this assay shows great potential as a practical diagnostic tool for HI infection in small laboratory settings.
Authors
- Yaling Cao (ORCID: https://orcid.org/0000-0002-4952-0643)
- Feng Ren (ORCID: https://orcid.org/0000-0001-7736-8637)
- Ling Xu (ORCID: https://orcid.org/0000-0002-7044-7663)
- Zihao Fan (ORCID: https://orcid.org/0000-0003-0011-8394)
- Junwen Wang (ORCID: https://orcid.org/0000-0002-5410-6287)
- Qiwen Yang (ORCID: https://orcid.org/0000-0001-7272-3900)
- Jing Huang
- Yinkang Mo
- Zhenzhen Pan
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Peking Union Medical College Hospital (CN)
- Ministry of Education (RO)
- Centre Hospitalier Universitaire de Liège (BE)
- Beijing YouAn Hospital (CN)
- Beijing Chuiyangliu Hospital (CN)
Publication Details
- Journal
- Journal of Clinical Microbiology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1128/jcm.00535-25
- Citations
- 3
- Primary Topic
- Biosensors and Analytical Detection
- Type
- article
- Field-Weighted Citation Impact
- 2.02